Northland Securities upgraded shares of vTv Therapeutics (NASDAQ:VTVT) from a market perform rating to an outperform rating in a report published on Monday, May 6th, The Fly reports.
Separately, Zacks Investment Research lowered vTv Therapeutics from a buy rating to a hold rating and set a $2.75 price target on the stock. in a research report on Saturday, January 19th.
Shares of vTv Therapeutics stock traded up $0.07 during trading on Monday, reaching $1.82. 2,785,184 shares of the company’s stock were exchanged, compared to its average volume of 1,115,475. The stock has a market capitalization of $91.58 million, a P/E ratio of -2.64 and a beta of -3.79. vTv Therapeutics has a 1-year low of $0.68 and a 1-year high of $6.09.
In related news, major shareholder Ronald O. Perelman acquired 1,358,698 shares of the stock in a transaction dated Wednesday, May 15th. The stock was purchased at an average cost of $1.84 per share, with a total value of $2,500,004.32. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.70% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of VTVT. Wedbush Securities Inc. bought a new position in vTv Therapeutics during the first quarter valued at $30,000. Morgan Stanley grew its holdings in vTv Therapeutics by 147,061.5% during the first quarter. Morgan Stanley now owns 19,131 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 19,118 shares during the period. Barclays PLC grew its holdings in vTv Therapeutics by 366.7% during the fourth quarter. Barclays PLC now owns 28,000 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 22,000 shares during the period. D. E. Shaw & Co. Inc. bought a new position in vTv Therapeutics during the fourth quarter valued at $186,000. Finally, Sabby Management LLC bought a new position in vTv Therapeutics during the first quarter valued at $382,000. 3.94% of the stock is owned by institutional investors.
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.
Featured Article: Put Option
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.